CRKL oncogene is downregulated by p53 through miR-200s

Area of Science:

• Molecular Biology
• Oncology
• Gene Regulation

Background:

• Tumor suppressive microRNAs (miRNAs) targeting oncogenes are often downregulated in cancer, leading to oncogene activation.
• The miR-200 family is frequently downregulated in cancer progression and metastasis.
• miR-200 family clusters are located on human chromosomes 1 and 12.

Purpose of the Study:

• To investigate the regulatory relationship between the p53 family and the miR-200 family.
• To identify and validate oncogenic targets of the miR-200 family.
• To explore the therapeutic potential of targeting the miR-200/CRKL axis in cancer.

Main Methods:

• In silico analysis to predict miRNA targets.
• Experimental validation of miR-200b/200c/429 targeting of CRKL mRNA and protein.
• Introduction of p53 family and activation of endogenous p53 in cancer cells.
• siRNA-mediated knockdown of CRKL.
• Analysis of CRKL expression in cancer tissues using the Oncomine database.

Main Results:

• p53 response elements were identified near miR-200 family clusters, confirming miR-200s as p53 transcriptional targets.
• CRKL was identified as a direct target of miR-200b/200c/429, leading to inhibition of CRKL mRNA and protein.
• Endogenous CRKL expression decreased in cancer cells upon p53 family introduction and activation.
• CRKL downregulation via siRNA inhibited cancer cell growth.
• CRKL is overexpressed in various cancers, notably in breast cancer with mutant TP53.

Conclusions:

• The p53-regulated miR-200b/200c/429 miRNAs act as negative regulators of the CRKL oncogene.
• The p53/miR-200/CRKL pathway represents a potential therapeutic target in cancers characterized by CRKL overexpression and p53 mutations.